Pancreatic Cancer Precision Medicine Market to Reach $2.5 Billion by 2033

The global pancreatic cancer precision medicine market is expected to reach US$ 2,467.83 million by 2033, up from US$ 610 million in 2024, expanding at a robust CAGR of 16.8% from 2025 to 2033. This rapid growth reflects the rising adoption of targeted therapies, immunotherapies, and advanced diagnostics such as liquid biopsies and genomic testing, all of which are enabling more personalized and effective treatment strategies.

Precision medicine in oncology focuses on identifying the unique molecular characteristics of a patient's tumor and matching those features with the most effective therapies. Technologies such as next-generation sequencing (NGS), molecular diagnostics, and biomarker-based companion diagnostics allow clinicians to detect actionable mutations, gene fusions, and protein expressions that can guide therapy selection. Liquid biopsies, which analyze circulating tumor DNA from blood samples, are making it possible to monitor disease progression and treatment response in a minimally invasive way.

In August 2024, PanTher Therapeutics announced that the U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for PTM-101, to proceed in a Phase Ib clinical study in patients with pancreatic ductal adenocarcinoma (PDAC). In July 2024, Diakonos Oncology Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to dendritic cell vaccine (DCV) for pancreatic ductal adenocarcinoma.

In May 2024, the FDA granted orphan drug designation to azeliragon (TTP488) for patients with pancreatic cancer. Azeliragon is a lead product candidate being developed by Cantex Pharmaceuticals. Also in May 2024, pancreatic cancer research received $8m philanthropic funding boost. This exceptional $8 million, 10-year philanthropic investment will spearhead new treatments for pancreatic cancer and create a new dedicated research centre at WEHI.

In May 2024, Oncolytics Biotech Inc. announced that it had entered into a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR). The purpose of the preliminary collaboration is to commence planning activities for the evaluation of pelareorep in the treatment of first-line metastatic pancreatic ductal adenocarcinoma (PDAC) as part of GCAR's anticipated master protocol for metastatic pancreatic cancer.

In March 2024, Catalan biopharmaceutical company AbilityPharma had secured a €7m ($7.65m) investment to progress its Phase IIb clinical trial of ABTL0812, an autophagy inducer that targets metastatic pancreatic cancer. In January 2024, Focal Medical has received clearance for its investigational new drug (IND) application from the US Food and Drug Administration (FDA) to commence a Phase Ib clinical trial for its investigational product, ACT-IOP-003, for pancreatic cancer.

The market growth is being propelled by several converging trends: increasing global incidence of pancreatic cancer, rapid advances in genomic and molecular diagnostic technologies, expanding pipelines of targeted and immune-based therapies, rising investment in oncology research and development, and stronger collaboration between pharmaceutical companies, biotech firms, and academic institutions.

ABRAXANE is a prescription medicine used to treat advanced pancreatic cancer, when used in combination with gemcitabine, as the first medicine for advanced pancreatic cancer. In September 2013, the FDA approved Abraxane in combination with gemcitabine to treat patients with late-stage pancreatic cancer. The approval was based on data from an international, multisite phase III clinical trial that compared 431 patients with metastatic pancreatic cancer who took nab-paclitaxel and gemcitabine with 430 patients who took gemcitabine alone. Patients treated with the nab-paclitaxel-gemcitabine combination lived an average of 1.8 months longer than those treated with gemcitabine alone.